9 Meters Biopharma, Inc. (NMTRQ)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Peter H. R. Green M.D. | Clinical & Scientific Advisor and Consultant | -- | -- | -- |
| Mr. Joseph A. Murray M.D. | Clinical & Scientific Advisor and Consultant | -- | -- | -- |
| Dr. Ciaran P. Kelly M.D. | Clinical & Scientific Advisor and Consultant | -- | -- | -- |
| Dr. Elena Verdu M.D., Ph.D. | Clinical & Scientific Advisor and Consultant | -- | -- | -- |
| Mr. Markku Mäki M.D., Ph.D. | Clinical & Scientific Advisor and Consultant | -- | -- | -- |
| Dr. Roger Liddle M.D. | Clinical & Scientific Advisor and Consultant | -- | -- | -- |
| Dr. Anthony J. Dimarino Jr. | Clinical & Scientific Advisor and Consultant | -- | -- | -- |
| Dr. Brian Gordon Feagan FRCPC, M.D., M.P.H. | Clinical & Scientific Advisor and Consultant | -- | -- | -- |
| Dr. Aida Habtezion M.D., M.Sc. | Clinical & Scientific Advisor and Consultant | -- | -- | -- |
| Dr. Steven M. Lipkin FACMG, M.D., Ph.D. | Clinical & Scientific Advisor and Consultant | -- | -- | -- |
9 Meters Biopharma, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 10
Description
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.
Corporate Governance
Recent Events
- Sep 08, 202325-NSE: Notification filed by national security exchange to report the removal from listing and registration of maturedSee Full Filing
- Jul 18, 20238-K: Corporate Changes & Voting MattersSee Full Filing
- Jun 16, 20238-K: Corporate Changes & Voting MattersSee Full Filing
- May 30, 20238-K: Corporate Changes & Voting MattersSee Full Filing
- May 22, 20238-K: Corporate Changes & Voting MattersSee Full Filing